Overview

The marketing authorisation for Riprazo has been withdrawn at the request of the marketing-authorisation holder.

български (BG) (267.39 KB - PDF)

View

español (ES) (188.34 KB - PDF)

View

čeština (CS) (236.86 KB - PDF)

View

dansk (DA) (188.88 KB - PDF)

View

Deutsch (DE) (250.26 KB - PDF)

View

eesti keel (ET) (187.97 KB - PDF)

View

ελληνικά (EL) (275.64 KB - PDF)

View

français (FR) (250.06 KB - PDF)

View

italiano (IT) (192.22 KB - PDF)

View

latviešu valoda (LV) (242.57 KB - PDF)

View

lietuvių kalba (LT) (217.51 KB - PDF)

View

magyar (HU) (229.63 KB - PDF)

View

Malti (MT) (235.53 KB - PDF)

View

Nederlands (NL) (188.74 KB - PDF)

View

polski (PL) (297.59 KB - PDF)

View

português (PT) (264.01 KB - PDF)

View

română (RO) (218.03 KB - PDF)

View

slovenčina (SK) (278.35 KB - PDF)

View

slovenščina (SL) (228.45 KB - PDF)

View

Suomi (FI) (265.85 KB - PDF)

View

svenska (SV) (249.95 KB - PDF)

View

Product information

български (BG) (902.17 KB - PDF)

View

español (ES) (619.59 KB - PDF)

View

čeština (CS) (789.29 KB - PDF)

View

dansk (DA) (637.46 KB - PDF)

View

Deutsch (DE) (669.55 KB - PDF)

View

eesti keel (ET) (654.53 KB - PDF)

View

ελληνικά (EL) (996.88 KB - PDF)

View

français (FR) (745.35 KB - PDF)

View

íslenska (IS) (675.49 KB - PDF)

View

italiano (IT) (757.31 KB - PDF)

View

latviešu valoda (LV) (810.27 KB - PDF)

View

lietuvių kalba (LT) (759.46 KB - PDF)

View

magyar (HU) (791.1 KB - PDF)

View

Malti (MT) (907.63 KB - PDF)

View

Nederlands (NL) (621.18 KB - PDF)

View

norsk (NO) (659.16 KB - PDF)

View

polski (PL) (843.1 KB - PDF)

View

português (PT) (721.42 KB - PDF)

View

română (RO) (689.67 KB - PDF)

View

slovenčina (SK) (835.24 KB - PDF)

View

slovenščina (SL) (788.82 KB - PDF)

View

Suomi (FI) (636.53 KB - PDF)

View

svenska (SV) (606.45 KB - PDF)

View

Latest procedure affecting product information: IG/0209/G

17/08/2012

icon globe

This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.

 

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

български (BG) (248.08 KB - PDF)

View

español (ES) (226.23 KB - PDF)

View

čeština (CS) (233.81 KB - PDF)

View

dansk (DA) (205.62 KB - PDF)

View

Deutsch (DE) (206.63 KB - PDF)

View

eesti keel (ET) (207.33 KB - PDF)

View

ελληνικά (EL) (250.29 KB - PDF)

View

français (FR) (209.37 KB - PDF)

View

íslenska (IS) (226.53 KB - PDF)

View

italiano (IT) (226.09 KB - PDF)

View

latviešu valoda (LV) (216.14 KB - PDF)

View

lietuvių kalba (LT) (539.5 KB - PDF)

View

magyar (HU) (241.81 KB - PDF)

View

Malti (MT) (235.35 KB - PDF)

View

Nederlands (NL) (226.03 KB - PDF)

View

norsk (NO) (228.5 KB - PDF)

View

polski (PL) (233.81 KB - PDF)

View

português (PT) (227.59 KB - PDF)

View

română (RO) (228.75 KB - PDF)

View

slovenčina (SK) (235.4 KB - PDF)

View

slovenščina (SL) (233.41 KB - PDF)

View

Suomi (FI) (228.05 KB - PDF)

View

svenska (SV) (227.48 KB - PDF)

View

Product details

Name of medicine
Riprazo
Active substance
aliskiren
International non-proprietary name (INN) or common name
aliskiren
Therapeutic area (MeSH)
Hypertension
Anatomical therapeutic chemical (ATC) code
C09XA02

Pharmacotherapeutic group

Agents acting on the renin-angiotensin system

Therapeutic indication

Treatment of essential hypertension.

Authorisation details

EMA product number
EMEA/H/C/000853
Marketing authorisation holder
Novartis Europharm Ltd.

Novartis Europharm Limited
Wimblehurst Road
Horsham
West Sussex, RH12 5AB
United Kingdom

Marketing authorisation issued
22/08/2007
Revision
8

Assessment history

This page was last updated on

Share this page